Efficacy and Safety of Canagliflozin in STEMI Patients with Type 2 Diabetes after PCI: A Retrospective Study
DOI:
https://doi.org/10.59958/hsf.7627Keywords:
ST segment elevation myocardial infarction, percutaneous coronary intervention, type 2 diabetes mellitus, canagliflozinAbstract
Objective: To assess the effectiveness and safety of canagliflozin in the management of ST segment elevation myocardial infarction (STEMI) patients with type 2 diabetes mellitus (T2DM) post-percutaneous coronary intervention (PCI). Methods: A retrospective analysis on data of patients diagnosed with STEMI and T2DM who underwent PCI treatment at our hospital was performed from June 2020 to September 2023. The patients were divided into two groups based on the exposure factor: the canagliflozin and conventional treatment groups and the canagliflozin and routine treatment groups. Various parameters, such as demographic characteristics, cardiac function indicators, and insulin-related factors, were collected and compared postprocedure. In addition, evaluation of the insulin sensitivity index (ISI), lipid profile parameters, and safety outcomes was conducted. A balanced baseline characteristics of patients was achieved via propensity score matching (PSM) at a 1:1 ratio. Statistical analyses were performed through t-tests, nonparametric tests, and chi-square tests. Results: This work included data on 156 patients, including 63 and 93 patients in the canagliflozin and routine treatment groups, respectively. Later, each group comprised 63 patients after 1:1 matching by PSM. After treatment, the canagliflozin treatment group exhibited notably reduced levels of N-terminal B-type natriuretic peptide, cardiac troponin T (cTnT), and creatine kinase-MB and a significantly higher level of left ventricular ejection fraction in comparison with the routine treatment group (p < 0.05). In addition, following treatment, the canagliflozin treatment group exhibited a significant decrease in homeostatic model assessment (HOMA)-insulin resistance levels and a significant increase in HOMA-β levels (p < 0.05). Conversely, the groups manifested no significant variances in terms of major adverse cardiovascular events, hypoglycemia, diabetic ketoacidosis, acute kidney injury, and urinary tract infection (p > 0.05). Conclusion: The concurrent administration of canagliflozin following PCI improves cardiac function, insulin sensitivity, and lipid profile in patients with STEMI and T2DM, which ultimately lowers the likelihood of cardiovascular incidents. Canagliflozin demonstrates favorable clinical safety profiles in such individuals and displays promising prospects for clinical utility.
References
Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Rydén L, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. Journal of the American College of Cardiology. 2004; 43: 585–591.
Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. Journal of the American College of Cardiology. 2000; 36: 355–365.
Yao W, Li J. Risk factors and prediction nomogram model for 1-year readmission for major adverse cardiovascular events in patients with STEMI after PCI. Clinical and Applied Thrombosis/Hemostasis. 2022; 28: 10760296221137847.
Lahnwong C, Palee S, Apaijai N, Sriwichaiin S, Kerdphoo S, Jaiwongkam T, et al. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury. Cardiovascular Diabetology. 2020; 19: 91.
Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, et al. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019; 139: 2528–2536.
Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. International Journal of Stroke. 2018; 13: 612–632.
Khan MS, Usman MS, Siddiqi TJ, Memon MM, Shah SJ, Khan SS. Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis. European Journal of Preventive Cardiology. 2019; 26: 1680–1682.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine. 2019; 380: 347–357.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine. 2019; 380: 2295–2306.
Tubaro M. ESC 2017 STEMI Guidelines: a step forward for a better cure. European Heart Journal. Cardiovascular Pharmacotherapy. 2018; 4: 133–135.
Dyson PA, Twenefour D, Breen C, Duncan A, Elvin E, Goff L, et al. Diabetes UK evidence-based nutrition guidelines for the prevention and management of diabetes. Diabetic Medicine. 2018; 35: 541–547.
Kojima T, Hikoso S, Nakatani D, Suna S, Dohi T, Mizuno H, et al. Impact of Hyperglycemia on Long-Term Outcome in Patients With ST-Segment Elevation Myocardial Infarction. The American Journal of Cardiology. 2020; 125: 851–859.
Minami T, Kameda A, Terauchi Y. An evaluation of canagliflozin for the treatment of type 2 diabetes: an update. Expert Opinion on Pharmacotherapy. 2021; 22: 2087–2094.
Sano R, Shinozaki Y, Ohta T. Sodium-glucose cotransporters: Functional properties and pharmaceutical potential. Journal of Diabetes Investigation. 2020; 11: 770–782.
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine. 2019; 381: 1995–2008.
Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. Journal of the American Heart Association. 2019; 8: e012356.
Zhou H, Hu S, Jin Q, Shi C, Zhang Y, Zhu P, et al. Mff-Dependent Mitochondrial Fission Contributes to the Pathogenesis of Cardiac Microvasculature Ischemia/Reperfusion Injury via Induction of mROS-Mediated Cardiolipin Oxidation and HK2/VDAC1 Disassociation-Involved mPTP Opening. Journal of the American Heart Association. 2017; 6: e005328.
Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. AJNR. American Journal of Neuroradiology. 2018; 39: E61–E76.
Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission [published correction appears in Redox Biology. 2024; 71: 103083]. Redox Biology. 2018; 15: 335–346.
Zhang Z, Li X, He J, Wang S, Wang J, Liu J, et al. Molecular mechanisms of endothelial dysfunction in coronary microcirculation dysfunction. Journal of Thrombosis and Thrombolysis. 2023; 56: 388–397.
Matthews DR, Wysham C, Davies M, Slee A, Alba M, Lee M, et al. Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program. Diabetes, Obesity & Metabolism. 2020; 22: 2199–2203.
Torimoto K, Okada Y, Goshima Y, Tokutsu A, Sato Y, Tanaka Y. Addition of canagliflozin to insulin improves glycaemic control and reduces insulin dose in patients with type 2 diabetes mellitus: A randomized controlled trial. Diabetes, Obesity & Metabolism. 2019; 21: 2174–2179.
Canyelles M, García-Osuna Á, Junza A, Yanes O, Puig N, Ordóñez-Llanos J, et al. The Capacity of APOB-Depleted Plasma in Inducing ATP-Binding Cassette A1/G1-Mediated Macrophage Cholesterol Efflux-But Not Gut Microbial-Derived Metabolites-Is Independently Associated with Mortality in Patients with ST-Segment Elevation Myocardial Infarction. Biomedicines. 2021; 9: 1336.
Nishimiya N, Tajima K, Imajo K, Kameda A, Yoshida E, Togashi Y, et al. Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease. Internal Medicine. 2021; 60: 3391–3399.
De Stefano A, Tesauro M, Di Daniele N, Vizioli G, Schinzari F, Cardillo C. Mechanisms of SGLT2 (Sodium-Glucose Transporter Type 2) Inhibition-Induced Relaxation in Arteries From Human Visceral Adipose Tissue. Hypertension. 2021; 77: 729–738.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine. 2017; 377: 644–657.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine. 2015; 373: 2117–2128.
